Evotec SE — M&A Activity 2016

Apr 19, 2016

News Details

Corporate | 19 April 2016 07:30

Evotec and Pierre Fabre sign multi-year compound management agreement

DGAP-News: Evotec AG / Key word(s): Alliance

2016-04-19 / 07:30
The issuer is solely responsible for the content of this announcement.

---

Hamburg, Germany - 19 April 2016: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced a multi-year compound
management agreement with Pierre Fabre Laboratories, the 2nd largest
private French pharmaceutical group.

Under the terms of the agreement, Evotec will manage Pierre Fabre's
compound collection (individual compounds and collection plates) out of its
state-of-the-art compound management facility in Toulouse, France. The
agreement covers an initial period of five years.

Laurent Audoly, Pierre Fabre Pharmaceuticals R&D Director, commented: "We
are delighted to announce this first partnership with Evotec who has become
a leading player in the Toulouse drug discovery ecosystem. With its
significant expertise in the field of compound management, Evotec will
undoubtedly be an important partner for Pierre Fabre to accelerate its
discovery and development pace in the fields of oncology, dermatology and
CNS."

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We welcome
Pierre Fabre as another partner who has entrusted their complete compound
management needs to our state-of-the-art operation in Toulouse. This
collaboration further validates our strategy to establish a
state-of-the-art compound management operation out of Toulouse for the
European market and cements our position as the world leader in outsourced
compound management. We look forward to a long and successful partnership
with Pierre Fabre."

No financial details were disclosed.

ABOUT PIERRE FABRE
Pierre Fabre is a private pharmaceuticals and dermo-cosmetics company
founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.2 billion
Euros* in 2015, spread over 130 countries. The company is structured around
two divisions: Pharmaceuticals (prescription drugs, consumer health care)
and Dermo-cosmetics (including the Europe and Asia market-leader brand Eau
Thermale Avène). Pierre Fabre employs some 11,000 people worldwide and owns
subsidiaries in 43 countries. In 2015, the company allocated 16 percent of
its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas:
oncology, dermatology, CNS and consumer health care.
Within the framework of their Open Innovation strategy, Pierre Fabre
Laboratories have always developed durable and valuable scientific
partnerships with innovators from public research institutions (CNRS,
Inserm, .), faculties and universities (Ecole Polytechnique de Lausanne,
Université de Saclay, .), international pharmaceutical laboratories
(Allergan, Abbvie, Maruho, .) and biotech companies (Array, BioPharma,
AbCheck, Cellectar, .).
Through the Group's controlling company Pierre Fabre Participations, Pierre
Fabre is 86% owned by the Pierre Fabre Foundation, a recognized
public-interest organization since 1999, around 8% by the company's
employees while balance is held as treasury stock.

To learn more, please go to www.pierre-fabre.com/en
*2015 financial results currently being audited

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute).The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 70 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI or UCB and
development partnerships with e.g. Janssen Pharmaceuticals in the field of
Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes,
with Pfizer in the field of organ fibrosis and with Second Genome in the
field of inflammatory diseases. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

---

2016-04-19 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

 End of News    DGAP News Service